# A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients

> **NCT03102398** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tritech Biopharmaceuticals Co., Ltd.** · enrollment: 26 (estimated)

## Conditions studied

- Erectile Dysfunction

## Interventions

- **DRUG:** TR-399 (5% Vardenafil HCl·3H2O, topical gel)

## Key facts

- **NCT ID:** NCT03102398
- **Lead sponsor:** Tritech Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-31
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2017-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03102398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03102398, "A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03102398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*